Journal of Psychosocial Nursing and Mental Health Services

Psychopharmacology 

Vagus Nerve Stimulation for Depression and Other Neuropsychiatric Disorders

Robert H. Howland, MD

Abstract

EXCERPT

In July 2005, vagus nerve stimulation (VNS) therapy was approved by the U.S. Food and Drug Administration for the adjunctive long-term treatment of chronic or recurrent depression for patients age 18 and older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. In this article, I describe the clinical studies of VNS for treatment-resistant depression (TRD), as well as preliminary studies investigating its use for other neuropsychiatric disorders.

Abstract

EXCERPT

In July 2005, vagus nerve stimulation (VNS) therapy was approved by the U.S. Food and Drug Administration for the adjunctive long-term treatment of chronic or recurrent depression for patients age 18 and older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. In this article, I describe the clinical studies of VNS for treatment-resistant depression (TRD), as well as preliminary studies investigating its use for other neuropsychiatric disorders.

Authors
Dr. Howland is Associate Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania.

The author acknowledges grant support from Cyberonics, Inc.

Address correspondence to Robert H. Howland, MD, Associate Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O’Hara Street, Pittsburgh, PA 15213; e-mail: HowlandRH@upmc.edu.

10.3928/02793695-20060901-02

Sign up to receive

Journal E-contents